"The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the f"...
Severe Allergic Reactions
RAGWITEK can cause systemic allergic reactions including anaphylaxis which may be lifethreatening. In addition, RAGWITEK can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Educate patients to recognize the signs and symptoms of these allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. Allergic reactions may require treatment with epinephrine. [See below]
Administer the initial dose of RAGWITEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of RAGWITEK.
Prescribe auto-injectable epinephrine to patients receiving RAGWITEK. Instruct patients to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency autoinjectable epinephrine. Instruct patients to seek immediate medical care upon use of auto-injectable epinephrine and to stop treatment with RAGWITEK. [See PATIENT INFORMATION]
See the epinephrine package insert for complete information.
RAGWITEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.
RAGWITEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine. These medications include:
Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine.
Alpha-adrenergic blockers, ergot alkaloids
Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine.
Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and certain antihistamines
The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.
Cardiac glycosides, diuretics
Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.
Upper Airway Compromise
RAGWITEK can cause local reactions in the mouth or throat that could compromise the upper airway [see ADVERSE REACTIONS]. Consider discontinuation of RAGWITEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.
Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see CONTRAINDICATIONS]. Discontinue RAGWITEK and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.
Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. RAGWITEK has not been studied in subjects with moderate or severe asthma.
Withhold immunotherapy with RAGWITEK if the patient is experiencing an acute asthma exacerbation. Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation of RAGWITEK.
Concomitant Allergen Immunotherapy
RAGWITEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
Stop treatment with RAGWITEK to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery or dental extraction.
Patient Counseling Information
Advise patients to read the FDA-approved patient labeling (Medication Guide) and to keep RAGWITEK and all medicines out of the reach of children.
Severe Allergic Reactions
Advise patients that RAGWITEK may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients about the signs and symptoms of these allergic reactions [see WARNINGS AND PRECAUTIONS]. The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria.
Ensure that patients have auto-injectable epinephrine and instruct patients in its proper use. Instruct patients who experience a severe allergic reaction to seek immediate medical care, discontinue RAGWITEK, and resume treatment only when advised by a physician to do so. [See WARNINGS AND PRECAUTIONS]
Advise patients to read the patient information for epinephrine.
Inform patients that the first dose of RAGWITEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local allergic reaction [see WARNINGS AND PRECAUTIONS].
Because of the risk of upper airway compromise, instruct patients with persistent and escalating adverse reactions in the mouth or throat to discontinue RAGWITEK and to contact their healthcare professional. [See WARNINGS AND PRECAUTIONS]
Because of the risk of eosinophilic esophagitis, instruct patients with severe or persistent symptoms of esophagitis to discontinue RAGWITEK and to contact their healthcare professional. [See WARNINGS AND PRECAUTIONS]
Instruct patients with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking RAGWITEK and contact their healthcare professional immediately [see WARNINGS AND PRECAUTIONS].
Instruct patients to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet. [See DOSAGE AND ADMINISTRATION]
Carcinogenesis, Mutagenesis, Impairment Of Fertility
No studies have been performed in animals to evaluate the carcinogenic potential of RAGWITEK.
Fertility studies have not been performed with Short Ragweed pollen allergen extract.
Use In Specific Populations
Pregnancy Category C
Animal reproduction studies have not been performed with RAGWITEK. It is also not known whether RAGWITEK can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RAGWITEK should be used during pregnancy only if clearly needed.
Because systemic and local adverse reactions with immunotherapy may be poorly tolerated during pregnancy, RAGWITEK should be used during pregnancy only if clearly needed.
It is not known if RAGWITEK is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RAGWITEK is administered to a nursing woman.
RAGWITEK is not approved for use in pediatric patients because safety and efficacy have not been established.
RAGWITEK is not approved for use in patients over 65 years of age because safety and efficacy have not been established.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/2/2014
Additional Ragwitek Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.